Loading...
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
BACKGROUND: Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK-positive non-small cell lung cancer (NSCLC). Alectinib has demonstrated robust CNS activity in both crizotinib-naïve and crizotinib-resistant settings. However, the CNS...
Na minha lista:
| Udgivet i: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6440803/ https://ncbi.nlm.nih.gov/pubmed/30529198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.12.002 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|